To include your compound in the COVID-19 Resource Center, submit it here.

For:
ads
Product Development
Daily Chart: comparing timelines of COVID-19 vaccines

Within a few months, preliminary data could be available from as many as eight more COVID-19 vaccines.

Front-runners Moderna Inc. and CanSino Biologics Inc. ...

‘A science problem we can solve:’ a BioCentury podcast

The scientific progress toward finding countermeasures against COVID-19 in the past five months is “unprecedented in the history of the world,” GSK’s Hal Barron said on the latest ...

CEPI funding fuels Novavax vaccine trial start, ex-U.S. manufacturing land grab

After enrolling the first volunteers in a Phase I/II trial for its COVID-19 vaccine, Novavax acquired a Czech company that will provide manufacturing capacity outside the U.S., ...

Mass General counts AveXis, James Wilson among partners as it readies to deploy gene therapy tools for COVID-19 vaccine

A Mass General program using gene therapy vectors to develop a COVID-19 vaccine has teed up the multilayered manufacturing capacity needed to get its AAV candidate into the clinic ...

Regulation
FDA warns of possible PDUFA delays due to COVID-19

FDA may not meet its goals for regulatory decisions during the COVID-19 pandemic, according to

Finance
argenx parlays myasthenia gravis data into year’s second-largest follow-on at $750M

In the year’s second-largest follow-on to date, argenx raised $750 million through the sale of 2.6 million ADSs

Read the full

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

Ginkgo financing to support COVID-19 testing
New investor Illumina Inc. (NASDAQ:ILMN) led a $70 million round on Thursday for genetic engineering company Ginkgo ...

Management Tracks
In new role as Flagship ‘CEO partner,’ Chouraqui to become Cellarity’s chief exec

Pharma veteran Fabrice Chouraqui is the first new hire at Flagship to take the title of CEO partner, but he likely won’t be the last.

Chouraqui will join ...

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

Assembly Biosciences Inc. (NASDAQ:ASMB) said Richard Colonno will retire as CSO, virology, on June 1. He is succeeded by William Delaney, who spent 20 years at ...

BioCentury ISSN 1097-7201